Tuesday, August 11, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Aug 10, 2026
ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms
background ▾
- •FDA rejection was purely CMC-related; clinical and safety data from the Compete trial were not questioned, preserving the drug's therapeutic potential and regulatory pathway
- •ITM-11 showed PFS superiority over Afinitor but lacked OS benefit, creating a clinical positioning challenge even if manufacturing issues are resolved
- •Manufacturing bottlenecks for specialized radiopharmaceuticals represent a material regulatory risk; ITM must optimize production with its contract manufacturing partner before resubmission
ITM Isotopes TechnologiesNovartisITM-11AfinitorPluvicto
→ Read original articlePolicy•Fierce Biotech•Aug 10, 2026
FDA issues alert in wake of BD recall of faulty needle sets
background ▾
- •FDA issued an early alert (pre-formal recall classification) for BD's intraosseous needle sets due to stylet removal failures in critically ill patients requiring emergency vascular access
- •Four deaths and 45 serious injuries reported; device defect involves out-of-tolerance dimensions causing obturator-needle hub locking, with causality to deaths not yet established
- •Monitor for formal recall classification and any design/manufacturing changes BD implements; assess impact on emergency medicine protocols and alternative IO device adoption
Becton DickinsonIntraosseous Vascular Access system needle sets
→ Read original articlePolicy•STAT News•Aug 11, 2026
Opinion: The new geography of abortion care
background ▾
- •Abortion care migration to non-clinical settings began before Dobbs, not after—suggesting longer-term patient adaptation to existing barriers rather than purely Supreme Court-driven response
- •Post-Dobbs, patient contact patterns shifted from pre-abortion planning to in-abortion support-seeking, indicating higher-risk, less-informed self-managed care
- •Watch for: regulatory actions against telehealth abortion providers, state-level shield law enforcement, and downstream safety/surveillance implications for medication abortion users
misoprostol
→ Read original articlePolicy•STAT News•Aug 11, 2026
IRBs have a problem. Can North Star’s nonprofit model save it?
background ▾
- •For-profit IRB model creates structural conflicts of interest that prioritize speed and legal compliance over participant welfare and evolving ethical standards (e.g., data privacy, exploitation risks)
- •2009 GAO sting operation found major for-profit IRB (Coast IRB) approved fictitious unethical protocol, yet systemic reform never followed, indicating regulatory and institutional inertia
- •Watch whether North Star's nonprofit model gains institutional adoption and regulatory support, and whether it catalyzes broader IRB system reform or remains a niche alternative
North Star Review BoardCoast IRB
→ Read original articlePolicy•Endpoints News•Aug 10, 2026
Trump directs MMR vaccine to be split in three parts, backs autism claim
background ▾
- •Trump administration is directly intervening in vaccine policy and manufacturing, directing MMR to be administered as three separate shots rather than the combined formulation—a reversal of current CDC guidance backed by substantial safety data.
- •The administration is publicly promoting the discredited vaccine-autism link, which was debunked by multiple large epidemiological studies and retracted landmark fraudulent research, signaling potential shifts in vaccine safety messaging and regulatory science standards.
- •Watch for regulatory responses from FDA/CDC, vaccine manufacturer compliance or pushback, impact on immunization rates and disease surveillance, and potential Congressional scrutiny of executive overreach into public health policy.
MerckAbbottSerum Institute of IndiaMMR vaccine
→ Read original articleMarket Access
Market Access•Fierce Biotech•Aug 10, 2026
Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
background ▾
- •ABS-1230 is the first and only investigational drug targeting KCNT1+ epilepsy, addressing a market with zero approved therapies and a severely disabled patient population (80% of patients develop the condition in infancy with profound developmental consequences)
- •Jazz's $820M upfront valuation reflects confidence in early clinical data and willingness to pay premium for rare disease precision therapies with clear regulatory pathways
- •Monitor phase 1b/2a trial progression and potential expedited regulatory designations (breakthrough therapy, orphan drug) that could accelerate Jazz's path to commercialization in a 2,500-patient U.S. market
Jazz PharmaceuticalsActio BiosciencesABS-1230EpidiolexABS-0871
→ Read original articleMarket Access•Fierce Biotech•Aug 10, 2026
Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
background ▾
- •Catalent's Bloomington facility has received an OAI designation from the FDA, indicating serious manufacturing violations that have triggered rejections or delays for at least three programs (Scholar Rock's apitegromab, Regeneron's Eylea prefilled syringe, and Regeneron's odronextamab), plus complications for Incyte's Zynyz approval
- •Scholar Rock's ability to pivot to a second fully-qualified fill-finish facility with demonstrated compliance history enables continuity of its September 30 FDA decision date, reducing apitegromab's regulatory risk in the near term
- •Watch the EMA's review of apitegromab and whether European regulators will accept the alternative fill-finish facility, as the EMA is currently holding its decision pending FDA inspection classification; broader industry monitoring for manufacturing disruptions at other Novo-owned CDMO sites post-acquisition
Scholar RockNovo NordiskCatalentapitegromabEyleaodronextamab
→ Read original articleMarket Access•STAT News•Aug 11, 2026
Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs
background ▾
- •Medicare's Bridge program creates significant administrative complexity for clinicians—including prior authorizations, documentation requirements, and evolving coverage rules—that may cause treatment delays and discourage provider participation despite the $50/month copay headline.
- •Cancellation of the Balance program and Bridge extension through 2027 creates a multi-year interim period where Medicare GLP-1 coverage remains fragmented, leaving uncertainty about permanent Part D integration and the trajectory of obesity treatment access for seniors.
- •Monitor whether actual GLP-1 utilization under Bridge meets CMS projections; lower uptake could be misinterpreted as demand weakness rather than operational failure, influencing future policy decisions on full Medicare coverage.
Novo NordiskEli LillyWegovyZepboundFoundayo
→ Read original articleMarket Access•Fierce Biotech•Aug 10, 2026
Labcorp nabs FDA green light for BRAF melanoma diagnostic
background ▾
- •Labcorp gains FDA clearance for a BRAF V600E/V600K companion diagnostic in melanoma, enabling faster patient stratification for existing targeted therapies
- •The competitive landscape includes at least four established BRAF diagnostic alternatives, suggesting limited market opportunity differentiation
- •Data retention capability may provide Labcorp with clinical research advantages and future revenue opportunities from biobanked samples
LabcorpNovartisRocheTafinlarZelboraf
→ Read original articleMarket Access•Fierce Biotech•Aug 10, 2026
Novo Nordisk and Amazon sign AI drug discovery pact, launch London innovation hub
background ▾
- •AWS becomes Novo Nordisk's preferred cloud and AI partner with a dedicated innovation hub, signaling major infrastructure consolidation and deepening of the existing Amazon-Novo commercial relationship beyond pharmacy and advertising.
- •Novo has already realized operational gains including reduced clinical documentation time and enhanced employee productivity, indicating the partnership is delivering near-term value.
- •Watch for pipeline acceleration metrics and publication of drug discovery outcomes using AWS tools; competitive responses from other pharma-cloud provider partnerships (e.g., J&J-AWS, Flagship-AWS) will indicate industry adoption pace.
Novo NordiskAmazon Web ServicesJohnson & Johnson
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Aug 10, 2026
Silence brings the noise to Takeda with phase 2 blood cancer win
background ▾
- •Divesiran achieved 88% response rate in phase 2 PV trial, with 93.8% response at the 6-week dosing interval, demonstrating clinically meaningful efficacy versus the upcoming competitor rusfertide (76.9% response in phase 3)
- •Silence's proposed quarterly IV dosing for phase 3 contrasts sharply with rusfertide's weekly self-administered injection, representing a potential competitive differentiation if demonstrated in late-stage trials
- •Watch for Silence's phase 3 trial initiation in H1 2025, rusfertide's Q3 2024 FDA decision, and whether Silence pursues financing to fund the pivotal program given $70.1M cash runway
Silence TherapeuticsTakedaProtagonist Therapeuticsdivesiranrusfertide
→ Read original articleClinical Trials•Fierce Biotech•Aug 10, 2026
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
background ▾
- •ABCL635 demonstrated placebo-adjusted efficacy of 5.3 hot flashes/day reduction at Week 4, nearly double the ~2.5 reduction seen with approved small-molecule NK3R inhibitors, suggesting potential best-in-class positioning
- •Clean safety profile with zero cases of elevated liver enzymes or bilirubin—a critical advantage over Veozah's hepatotoxicity liability and associated monitoring burden
- •Phase 3 trial design and development strategy to be determined; company must replicate safety findings and confirm efficacy advantage in larger pivotal studies to realize commercial potential
AbCelleraAstellasBayerABCL635VeozahLynkuet
→ Read original articleClinical Trials•Fierce Biotech•Aug 10, 2026
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
background ▾
- •Sonelokimab met all primary and secondary efficacy endpoints in biologic-naïve PsA patients, with clinically meaningful response rates across multiple measures (ACR50, ACR20, MDA, PASI90), supporting advancement to potential registration
- •The nanobody modality with dual IL-17A/F and albumin binding represents a differentiated mechanism versus FDA-approved therapies, though clinical superiority versus existing standards of care remains unproven pending Izar-2 head-to-head data with Skyrizi
- •Watch for: Izar-2 comparative efficacy data (vs. Skyrizi in TNF-inhibitor-experienced patients) expected H1 2027; regulatory pathway and market positioning strategy in crowded PsA space; Phase 3 hidradenitis suppurativa and axial spondyloarthritis readouts to validate platform
MoonLake ImmunotherapeuticsMerck KGaAAbbViesonelokimabSkyriziHumira
→ Read original articleClinical Trials•Fierce Biotech•Aug 10, 2026
Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex
background ▾
- •SION-719 failed to demonstrate clinically meaningful efficacy as an add-on to Vertex's Trikafta, falling far short of both company and expert-set benchmarks for sweat chloride reduction.
- •Vertex's competitive position in cystic fibrosis is substantially strengthened with removal of a well-funded competitor, reinforcing the company's dominance in what remains a highly profitable franchise.
- •Sionna's path forward depends on whether phase 1 data for SION-451 plus SION-2222 combination can justify continued development; capital preservation measures suggest limited runway for clinical advancement.
Sionna TherapeuticsVertex PharmaceuticalsSION-719SION-451SION-2222
→ Read original articleClinical Trials•Endpoints News•Aug 10, 2026
AbCellera details 'striking' Phase 2 data for vasomotor symptoms treatment
background ▾
- •Phase 2 vasomotor symptoms trial met or exceeded primary endpoint expectations, generating strong market confidence as evidenced by substantial stock appreciation
- •Positive mid-stage data in hot flashes/vasomotor symptoms represents potential differentiation in a category with limited non-hormonal options
- •Full trial data readout details and regulatory pathway (likely FDA NDA) timing should clarify commercial potential and competitive landscape
AbCellera
→ Read original article